These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6269489)

  • 1. Immunological properties of beta-lactamases that hydrolyze cefuroxime and cefotaxime.
    Hirai K; Sato K; Matsubara N; Katsumata R; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1981 Aug; 20(2):262-4. PubMed ID: 6269489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A beta-lactamase from Proteus vulgaris that hydrolyses newly introduced cephalosporins.
    Pagani L; Perduca M; Romero E
    Microbiologica; 1983 Apr; 6(2):163-8. PubMed ID: 6306402
    [No Abstract]   [Full Text] [Related]  

  • 3. Interaction of cefdinir with beta-lactamases.
    Labia R; Morand A
    Drugs Exp Clin Res; 1994; 20(2):43-8. PubMed ID: 7924895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interactions of ceftriaxone with beta-lactamases including those which hydrolyze cefotaxime].
    Labia R; Morand A; Kazmierczak A
    Pathol Biol (Paris); 1986 Oct; 34(8):908-12. PubMed ID: 3537935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M
    Antimicrob Agents Chemother; 1979 Dec; 16(6):757-60. PubMed ID: 316989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
    Beale AS; Gisby J
    J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity of cefmenoxime for beta-lactamases: an analysis.
    Labia R; Morand A; Verchere-Beaur C; Bryskier A
    Am J Med; 1984 Dec; 77(6A):25-7. PubMed ID: 6097119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of Ro 13-99041 as a substrate and inhibitor of beta-lactamases.
    Then RL
    Chemotherapy; 1981; 27 Suppl 1():25-31. PubMed ID: 6972858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime.
    Hiraoka M; Masuyoshi S; Mitsuhashi S; Tomatsu K; Inoue M
    J Antibiot (Tokyo); 1988 Jan; 41(1):86-93. PubMed ID: 3279015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of cephalosporinase from Proteus morganii.
    Toda M; Inoue M; Mitsuhashi S
    J Antibiot (Tokyo); 1981 Nov; 34(11):1469-75. PubMed ID: 6976340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and some properties of beta-lactamases from Proteus rettgeri and Proteus inconstans.
    Ohya S; Fujii-Kuriyama Y; Yamamoto M; Sugawara S
    Microbiol Immunol; 1980; 24(9):815-24. PubMed ID: 6971391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of HR-756, cefoxitin and cefuroxine against multiply antibiotic-resistant strains of Enterobacteriaceae and Pseudomonas aeruginosa.
    Legakis NJ; Kafetzis DA; Papadatos CJ; Papavassiliou JT
    Chemotherapy; 1980; 26(5):334-43. PubMed ID: 6248301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents.
    Mouton RP; Bongaerts GP; van Gestel MH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():147-52. PubMed ID: 19802978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefotaxime-hydrolysing beta lactamases in Morganella morganii.
    Power P; Radice M; Barberis C; de Mier C; Mollerach M; Maltagliatti M; Vay C; Famiglietti A; Gutkind G
    Eur J Clin Microbiol Infect Dis; 1999 Oct; 18(10):743-7. PubMed ID: 10584905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime.
    Fu KP; Neu HC
    J Antibiot (Tokyo); 1979 Sep; 32(9):909-14. PubMed ID: 315938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrolytic rate at low drug concentration as a limiting factor in resistance to newer cephalosporins.
    Hiraoka M; Inoue M; Mitsuhashi S
    Rev Infect Dis; 1988; 10(4):746-51. PubMed ID: 3055173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TEM beta-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis.
    Raquet X; Lamotte-Brasseur J; Fonzé E; Goussard S; Courvalin P; Frère JM
    J Mol Biol; 1994 Dec; 244(5):625-39. PubMed ID: 7990143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of cefpirome and a cephalosporinase from Citrobacter freundii GN7391.
    Satake S; Hiraoka M; Mitsuhashi S
    Antimicrob Agents Chemother; 1989 Mar; 33(3):398-9. PubMed ID: 2658787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of cefamandole, cefoxitin, cefuroxime, cefotaxime and cefoperazone: an in vitro test on a number of beta-lactamase producing strains of 9 species and 1 genus of bacteria.
    Kuipers JS
    Curr Med Res Opin; 1981; 7(3):196-203. PubMed ID: 6971210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antimicrobial activity of cefotaxime, a new cephalosporin.
    Masuyoshi S; Arai S; Miyamoto M; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Jul; 18(1):1-8. PubMed ID: 6251749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.